Foviscu becomes the fifth proprietary antibiotic from Wockhardt to complete a registration-enabling phase 3 study, following Emrok, Emrok O, Miqnaf and Zaynich, Wockhardt said.
Foviscu becomes the fifth proprietary antibiotic from Wockhardt to complete a registration-enabling phase 3 study, following Emrok, Emrok O, Miqnaf and Zaynich, Wockhardt said.